Compare WBX & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WBX | STRO |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.0M | 85.0M |
| IPO Year | N/A | 2018 |
| Metric | WBX | STRO |
|---|---|---|
| Price | $2.37 | $11.59 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 8 |
| Target Price | $9.00 | ★ $18.29 |
| AVG Volume (30 Days) | 33.3K | ★ 120.7K |
| Earning Date | 02-26-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $174,593,453.00 | $105,646,000.00 |
| Revenue This Year | N/A | $63.08 |
| Revenue Next Year | $37.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.30 | $5.23 |
| 52 Week High | $14.40 | $21.50 |
| Indicator | WBX | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 24.77 | 79.96 |
| Support Level | $2.49 | $8.49 |
| Resistance Level | $3.36 | $12.00 |
| Average True Range (ATR) | 0.20 | 0.84 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 6.13 | 84.03 |
Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.